Cerebrotech Appoints Neurovascular Veteran as Executive Chairman

Cerebrotech Medical Systems, a medical device company developing a portable brain bioimpedance monitor, has appointed board member Martin Dieck, an experienced entrepreneur with expertise in developing novel neurovascular solutions, as executive chairman, effectively immediately.
 
“I am thrilled to have Martin move into a more substantial role as we enter the next exciting phase of our company,” said Mitch Levinson, president and CEO, Cerebrotech Medical Systems. “The strong relationships that Martin has built with experts in the neurotechnology field and his deep experience and understanding of the stroke marketplace are invaluable to Cerebrotech. I am looking forward to working closely with him in his new role.”
 
With nearly 25 years of experience in the neurovascular industry, Dieck has successfully directed several neurotechnology companies. Dieck co-founded and was CEO of Lazarus Effect Inc., a vascular interventional device to improve acute ischemic stroke treatment, which was acquired in 2015 by Medtronic plc for $100 million. Dieck also led Nfocus Neuromedical Inc., a developer of neurovascular intravascular devices, and Concentric Medical Inc., which developed the first cleared thrombectomy device to treat large vessel ischemic stroke, which were acquired by Covidien and Stryker Corp., respectively. He is currently chairman of Synchron Inc., which is developing the world’s first endovascular brain-machine interface.
 
“I am eager to take on this new role. Cerebrotech’s technology has the potential to transform the care of patients suffering from stroke and other brain diseases,” commented Dieck. “Getting appropriate stroke patients to the right center remains one of healthcare’s greatest challenges. Frequently, hours are lost correctly identifying stroke patients, thereby delaying their treatment, leading to higher costs and, most importantly, poorer patient outcomes. This technology can lead to millions of lives saved.”
 
In July, Cerebrotech presented the VITAL study results of its proprietary VIPS technology for emergency stroke patients at The Society of NeuroInterventional Surgery annual meeting. The results demonstrated that Cerebrotech’s non-invasive visor-like neurological device can identify those patients with large vessel occlusion (LVO) strokes and large hemorrhagic strokes versus those with less urgent strokes, allowing for earlier intervention to prevent further brain damage.
 
Cerebrotech Medical Systems is a venture capital-backed company designing neurotechnology solutions to improve the care of brain-injured patients worldwide. The company is developing a portable, noninvasive neuro-monitoring device that allows for earlier detection of potentially life-threatening conditions such as large vessel occlusion stroke, cerebral edema, traumatic brain injury, and others. Founded in 2010 and based in Pleasanton, Calif., Cerebrotech’s core intellectual property is licensed exclusively from the University of California at Berkeley. Cerebrotech is backed by Tri-Star Health Partners, a healthcare-focused venture capital firm; Mountain Group Partners, a life sciences and technology-focused venture capital firm; and Neuro Technology Investors, a group of physician investors in the neuro space.